Assembly Biosciences(NASDAQ) ASMB

Assembly Biosciences, Inc. develops medicines to treat chronic viral infections. These drugs help patients with long-term liver and skin diseases. The company creates therapies to stop viruses from spreading.

Target Areas for New Medicines

• Herpes Simplex Program: Investigational therapies for recurrent genital herpes designed to block specific viral enzymes; currently licensed to Gilead Sciences.
• Liver Disease Candidate: Small molecule entry inhibitor for chronic hepatitis delta virus and cholestatic liver diseases; preparing for Phase 2 trials.
• Capsid Assembly Modulators: Next-generation compounds designed to disrupt the life cycle of the hepatitis B virus and prevent viral persistence.
• Transplant-Related Program: Broad-spectrum treatments for herpesviruses that reactivate in patients with suppressed immune systems following organ transplants.

Recent Strategic Expansion

• Started a multiyear collaboration with Gilead Sciences in Oct. 2023 to develop viral disease treatments.
• Received a net $35 million payment in Dec. 2025 after Gilead licensed the genital herpes program.
• Management completed a $115.0 million financing transaction in May 2026 to support clinical trials through 2028.
• Expanded the clinical development of its lead candidate into two new liver disease indications in May 2026.

What Makes the Science Different?

The company develops oral medications that target viruses at multiple stages of their life cycle. These treatments focus on blocking the way viruses enter human cells and how they replicate once inside. These therapies aim to reduce the frequency of outbreaks and the risk of transmitting infections to others.

Cash Position and Financial Performance

• Collaboration revenue was $13.4 million for the three months ended June 30, 2026, up 39% year over year.
• Market capitalization rose to $518.1 million in the second quarter of 2026, up 273.5% year over year.
• Research and development expenses were $14.9 million for the three months ended June 30, 2026, down 7% year over year.
• Cash, cash equivalents, and marketable securities totaled $320.4 million as of June 30, 2026.

Bottom Line

Assembly Biosciences has evolved into a clinical-stage developer supported by a major partnership with Gilead Sciences. Its focus on long-acting oral therapies targets significant unmet needs in the viral and liver disease markets.